CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative form of immunotherapy used to treat certain types of cancer in children, particularly acute leukemias and lymphomas. The principle of CAR-T therapy is based on modifying the patientβs own T cells so that they are trained to recognize and destroy cancer cells. This approach has demonstrated high efficacy in the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL) in children.
How does CAR-T therapy work?
- T-cell collection. A blood sample is taken from the patient, from which T lymphocytes (immune system cells responsible for fighting infections and cancer) are isolated.
- Genetic modification. In a laboratory, the T cells are genetically engineered to introduce genes that enable them to produce specific receptors known as chimeric antigen receptors (CARs). These receptors allow T cells to recognize and attack cancer cells.
- Cell expansion. The modified T cells are multiplied in the laboratory to generate a sufficient number of cells for therapy.
- CAR-T cell infusion. The modified T cells are infused back into the patientβs body, where they begin to seek out and destroy cancer cells throughout the body.
Indications for CAR-T therapy in children
- Acute lymphoblastic leukemia (ALL). CAR-T therapy is indicated for children with ALL who have not responded to standard treatment (chemotherapy) or who have experienced relapse.
- Diffuse large B-cell lymphoma (DLBCL). In certain cases, CAR-T therapy may be used for lymphomas that are refractory to other treatment modalities.
CAR-T therapy is not effective for all types of cancer, and research into its broader applications is ongoing.
CAR-T therapy procedure
- Preparatory phase. Before CAR-T cell infusion, patients may receive low-dose chemotherapy (lymphodepleting therapy) to reduce the number of existing lymphocytes and create a more favorable environment for CAR-T cell expansion.
- CAR-T cell infusion. CAR-T cells are administered via intravenous infusion. Following infusion, the cells actively target and eliminate cancer cells.
- Monitoring and observation. Patients are closely monitored for several weeks after infusion to detect potential side effects and assess treatment effectiveness. This monitoring is usually carried out in a specialized medical center.
Efficacy of CAR-T therapy
- High remission rates. Many children with ALL who did not respond to other treatments experience significant improvement after CAR-T therapy, and some achieve complete remission.
- Duration of response. In some patients, remission can be long-lasting, although relapses may occur. Ongoing studies aim to better understand the long-term efficacy and safety of CAR-T therapy.
Long-term follow-up
- Regular follow-up examinations. After CAR-T therapy, children require regular medical evaluations to monitor overall health, detect possible relapse, and manage late effects.
- Immune support. Some patients may require regular immunoglobulin replacement therapy to support immune function.
- Psychological support. Cancer treatment can be highly stressful for children and their families. Psychological counseling and supportive care can help address emotional challenges.
Advantages of CAR-T therapy in Belarus
- Personalized approach. CAR-T therapy is individually designed for each patient using their own immune cells.
- High effectiveness. Even in children with severe, treatment-resistant leukemia, CAR-T therapy has shown remarkable results.
- New treatment opportunities. CAR-T therapy opens new perspectives for cancer treatment, particularly for patients with limited therapeutic options.
CAR-T therapy in children represents a revolutionary treatment approach that has brought hope to many families facing severe forms of cancer. Although the therapy may be associated with serious risks, its potential to achieve remission is significant. Patients and their families should work closely with healthcare professionals to fully understand all aspects of the treatment, including its benefits and possible complications.
Q&A
ΠΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ° ΠΈ ΠΌΠΎΠ΄ΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π’-ΠΊΠ»Π΅ΡΠΎΠΊ Π² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΠΈ ΠΌΠΎΠ³ΡΡ Π·Π°Π½ΡΡΡ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π½Π΅Π΄Π΅Π»Ρ. ΠΠ° ΡΡΠΎ Π²ΡΠ΅ΠΌΡ ΠΏΠ°ΡΠΈΠ΅Π½Ρ ΠΌΠΎΠΆΠ΅Ρ ΠΏΠΎΠ»ΡΡΠ°ΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΈΠ²Π°ΡΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ.
Π Π½Π΅ΠΊΠΎΡΠΎΡΡΡ ΡΠ»ΡΡΠ°ΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ ΠΏΠΎΠ²ΡΠΎΡΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅, Π½ΠΎ ΡΡΠΎ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠ°ΠΊΠ°.
Π Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΌΠΎΠ³ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ Ρ ΠΈΠΌΠΈΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ, ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΡ ΡΡΠ²ΠΎΠ»ΠΎΠ²ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈΠ»ΠΈ Π΄ΡΡΠ³ΠΈΠ΅ Π²ΠΈΠ΄Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ.
